Education
About Us
Working with TipRanks
Follow Us
Mainz Biomed B.V. (MYNZ)
NASDAQ:MYNZ
MYNZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.30 - $18.38
Previous CloseN/A
Volume20.13K
Average Volume (3M)187.01K
Market Cap
$5.61M
Enterprise ValueN/A
Total Cash (Recent Filing)$6.24M
Total Debt (Recent Filing)$3.27M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Sep 03, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,577,853
10 Day Avg. Volume200,654
30 Day Avg. Volume187,009
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$14.00Price Target Upside865.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Market OpportunityMainz Biomed is an emerging player in the $4B colorectal cancer (CRC) screening market with at-home, fecal-based, testing kits, presenting a substantial market opportunity.
Partnerships And StrategyDecentralized commercial strategy includes partnering with lab groups to reduce marketing and infrastructure expenses, and gain access to large physician networks.
Technological InnovationThe company's Next Generation Test leverages mRNA biomarkers to expand the ability to detect pre-cancerous advanced adenomas (AAs), enabling prevention of CRC.
Bears Say
Competitive MarketExisting tests with a similar format, such as Cologuard, have achieved commercial success with over $2B in annual sales, presenting strong competition for Mainz Biomed.
Feasibility And ValidationThe feasibility study seeks to evaluate the panel and machine learning algorithm in a clinical sample set to determine sensitivity, specificity, and consistency, posing a risk if results don't meet expectations.
Mainz Biomed B.V. News
MYNZ FAQ
What was Mainz Biomed B.V.’s price range in the past 12 months?
Mainz Biomed B.V. lowest stock price was $1.30 and its highest was $18.38 in the past 12 months.
What is Mainz Biomed B.V.’s market cap?
Mainz Biomed B.V.’s market cap is $5.61M.
When is Mainz Biomed B.V.’s upcoming earnings report date?
Mainz Biomed B.V.’s upcoming earnings report date is Sep 03, 2025 which is in 26 days.
How were Mainz Biomed B.V.’s earnings last quarter?
Currently, no data Available
Is Mainz Biomed B.V. overvalued?
According to Wall Street analysts Mainz Biomed B.V.’s price is currently Undervalued.
Does Mainz Biomed B.V. pay dividends?
Mainz Biomed B.V. does not currently pay dividends.
What is Mainz Biomed B.V.’s EPS estimate?
Mainz Biomed B.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mainz Biomed B.V. have?
Mainz Biomed B.V. has 4,577,853 shares outstanding.
What happened to Mainz Biomed B.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mainz Biomed B.V.?
Currently, no hedge funds are holding shares in MYNZ
Company Description
Mainz Biomed B.V.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
MYNZ Stock 12 Month Forecast
Average Price Target
$14.00
▲(865.52% Upside)
Technical Analysis
Trinity Biotech
―
Precipio
―
BioNano Genomics
―
Intelligent Bio Solutions
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
5.43% Other Institutional Investors
94.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---